Inventor
Erica ULLMAN
Inventor
US
Overview
Patents· 9 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes30%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
C07KPeptides30%
C12NMicroorganisms or enzymes10%
PatentTitleYear
12,590,168Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof202612,528,851IL2-based therapeutics and methods of use thereof202612,522,638IL12 receptor agonists and methods of use thereof202612,441,800Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof202511,905,332Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof202411,692,032Anti-LAG3 antibodies and uses thereof202311,548,947Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof202311,453,721Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof202211,396,544Bispecific anti-CD28 x anti-CD22 antibodies and uses thereof2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to REGENERON PHARMA (9)· patent assignee history
2022Patents assigned to REGENERAN PHARMACEUTICALS INC (1)· patent assignee history
2022–2026Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| REGENERON PHARMA | 9 | 2022–2026 |
| REGENERAN PHARMACEUTICALS INC | 1 | 2022 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 9 | 2022–2026 |